Showing promise in the arena of obesity treatment, retatrutide presents a unique approach. Beyond many available medications, retatrutide works as a dual agonist, simultaneously targeting both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This simultaneous activation encourages several helpful eff